Sugi Predict

Sugi Predict / Compounds / SCHEMBL5066090

SCHEMBL5066090

SCHEMBL5066090

Clc1cc2[nH]ncc2cn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS1 P29475 6/20 0.53
▸ DYRK1A Q13627 2/20 0.53
▸ CHEK1 O14757 1/20 0.47
▸ MAPT P10636 4/20 0.44
▸ METAP2 P50579 3/20 0.44
▸ KDM4E B2RXH2 3/20 0.44
▸ MEN1 O00255 3/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ PKM P14618 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ FGFR1 P11362 3/20 0.43
▸ HSP90AA1 P07900 1/20 0.40
▸ IDO1 P14902 1/20 0.40
▸ CDK2 P24941 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ GAA P10253 2/20 0.39
▸ CSNK2A1 P68400 1/20 0.39
▸ ROCK2 O75116 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29366050 1.00 NOS1 (0.53) NOS1DYRK1ACHEK1MAPTMETAP2
SCHEMBL16179044 0.83 NOS1 (0.53) NOS1DYRK1ACHEK1MAPTMETAP2
SCHEMBL29545399 0.83 NOS1 (0.53) NOS1DYRK1ACHEK1MAPTMETAP2
SCHEMBL30457395 0.74 NOS1 (0.53) NOS1DYRK1ACHEK1MAPTMETAP2
SCHEMBL16339586 0.74 NOS1 (0.53) NOS1DYRK1ACHEK1MAPTMETAP2
SCHEMBL14675972 0.74 CHEK1 (0.57) NOS1DYRK1ACHEK1MAPTMETAP2
SCHEMBL29490938 0.74 CHEK1 (0.57) NOS1DYRK1ACHEK1MAPTMETAP2
SCHEMBL8285951 0.74 CHEK1 (0.47) NOS1DYRK1ACHEK1MAPTMETAP2
SCHEMBL29425049 0.74 CHEK1 (0.47) NOS1DYRK1ACHEK1MAPTMETAP2
SCHEMBL3590783 0.73 NOS1 (0.57) NOS1DYRK1ACHEK1MAPTMETAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116888-A1 CYCLIN-DEPENDENT KINASE INHIBITORS NOVARTIS AG (CH) 2026-04-30 — — US disclosed
US-20260098049-A1 KRAS MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2026-04-09 — — US disclosed
EP-4674841-A2 PHARMACEUTICAL COMPOUND Duke Street Bio Limited (GB) 2026-01-07 — — EP disclosed
WO-2025242880-A1 THERAPEUTIC COMPOUNDS AND THEIR USE MY-T BIO LIMITED (GB) 2025-11-27 — — WO disclosed
US-20250304577-A1 TYK2 INHIBITORS BIOGEN MA INC. 2025-10-02 — — US disclosed
US-20250282785-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2025-09-11 — — US disclosed
EP-4583977-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2025-07-16 — — EP disclosed
US-20250221988-A1 COMPOUNDS AND METHODS OF TREATING CANCERS CULLGEN (SHANGHAI), INC. (CN) 2025-07-10 — — US disclosed
EP-4563579-A1 MACROCYCLIC EGFR INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2025-06-04 — — EP disclosed
WO-2025111251-A1 COMPOUNDS THAT INHIBIT POLO-LIKE KINASE 4 EXELIXIS, INC. (US) 2025-05-30 — — WO disclosed
WO-2013169704-A2 TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE MERCK SHARP & DOHME CORP. (US) 2013-11-14 — — WO disclosed
WO-2013063214-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-05-02 — — WO disclosed
WO-2013063214-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-05-02 — — WO disclosed
WO-2013041605-A1 PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES AS KINASE INHIBITORS CELLZOME LIMITED (GB) 2013-03-28 — — WO disclosed
WO-2013017479-A1 PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES AS JAK INHIBITORS CELLZOME LIMITED (GB) 2013-02-07 — — WO disclosed
WO-2013017480-A1 PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES AS JAK INHIBITORS CELLZOME LIMITED (GB) 2013-02-07 — — WO disclosed
WO-2013017480-A1 PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES AS JAK INHIBITORS CELLZOME LIMITED (GB) 2013-02-07 — — WO disclosed
WO-2013017479-A1 PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES AS JAK INHIBITORS CELLZOME LIMITED (GB) 2013-02-07 — — WO disclosed
US-20080081817-A1 Nitrogenous Fused Bicyclic Compound TANABE SEIYAKU CO., LTD. (JP) 2008-04-03 — — US disclosed
EP-1772454-A1 NITROGENOUS FUSED BICYCLIC COMPOUND TANABE SEIYAKU CO., LTD. (JP) 2007-04-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304577-A1 TYK2 INHIBITORS TYK2, JAK2, JAK1 NOS1 4405/4885DYRK1A 42/4885CHEK1 288/4885
US-20260116888-A1 CYCLIN-DEPENDENT KINASE INHIBITORS CDK4, CCNC, CDK6 NOS1 4257/4885DYRK1A 1214/4885CHEK1 53/4885
US-20250221988-A1 COMPOUNDS AND METHODS OF TREATING CANCERS GSPT1, GSS, G6PC1 NOS1 1108/4885DYRK1A 2883/4885CHEK1 1944/4885
US-20250282785-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE NFKBIA, IKBKG, IKBKB NOS1 297/4885DYRK1A 2524/4885CHEK1 1018/4885
US-20260098049-A1 KRAS MODULATING COMPOUNDS KRAS, NRAS, HRAS NOS1 4710/4885DYRK1A 2261/4885CHEK1 79/4885
US-20080081817-A1 Nitrogenous Fused Bicyclic Compound KCNH2, KCNN2, KCNN1 NOS1 653/4885DYRK1A 3756/4885CHEK1 3250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.